P3‐356: Bionetwork‐based study of combinational therapeutic targets for Alzheimer's disease: A practice for network pharmacology

Abstract

Network pharmacology broke through the traditional concept of “a disease, a gene, a drug,” and represents the modern philosophy and pattern of biomedical research as a new branch of pharmacology.The discovery of network-based combinational targets for Alzheimer's disease (AD) was conducted by using network pharmacology strategy in the study. Animal model such as SAMP8 mice, Cell model such as SH-SY5Y, learning and memory test, microarray, proteomics, bioinformatics and computational biology techniques were used. A total number of 81 related molecules were obtained from the hippocampus and cerebral cortex of SAMP8 and all the molecules were changed regularly with ageing process, and the molecule networks including those molecules were cnducted and the network-based combinational targets for AD were predicted. Nine typical molecules, such as AMFR, STUB1, NF-L, NDUFS2, CAMK2A, EphB6, CSTN1, NRXN1 and NGRN were validated and mapping in the networks. The candidate molecules for the network-based combinational targets for AD are closely related with pathophysiological processes of AD, and may become the members of the “combinational targets,” which is worthy of further studies.